International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaWilliam D. Travis, David Yankelewitz, Gregory J. Riely et al.|Journal of Thoracic Oncology|2011Cited by 4.8k
OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 TrialMyung‐Ju Ahn, D. Kim, D. Ross Camidge et al.|Journal of Thoracic Oncology|2017Cited by 20
Endobronchial laser therapy — Differential therapeutic use and clinical valueK Häußinger, Rudolf M. Huber, E. Held|Journal of Molecular Medicine|1984Cited by 13
P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA TrialD. Ross Camidge, D. Kim, Marcello Tiseo et al.|Journal of Thoracic Oncology|2017Cited by 3